1.77

1.14% 0.02

After Hours: 1.77

Iterum Therapeutics Plc (ITRM)

Overview News Price History Financials Why ITRM Down? Discussions Forecast Stock Split

Iterum Therapeutics Plc stock is traded at $1.77, with a volume of 666.55K. It is up +1.14% in the last 24 hours and up +8.59% over the past month. Iterum Therapeutics PLC is a clinical-stage pharmaceutical company. The company is engaged in developing and commercializing sulopenem to be the first and only oral and intravenous branded penem available globally. Its sulopenem program has the potential to offer a solution to the problem of antibiotic resistance and the toxicity limitations of existing agents. The company operates as a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.

Previous Close:

$1.75

Open:

$1.75

24h Volume:

666.55K

Relative Volume:

0.24

Market Cap:

$48.70M

Revenue:

Net Income/Loss:

$-35.58M

P/E Ratio:

-0.3916

EPS:

-4.52

Net Cash Flow:

$-42.82M

1W Performance:

-1.67%

1M Performance:

+8.59%

6M Performance:

+53.91%

1Y Performance:

+5.99%

1-Day Range:

$1.75

$1.81

1-Week Range:

$1.625

$1.9493

52-Week Range:

$0.808

$3.02

Iterum Therapeutics Plc Stock (ITRM) Company Profile

Name

Iterum Therapeutics Plc

Sector

Healthcare (1176)

Industry

Biotechnology (673)

Phone

(872) 225-6077

Address

FITZWILLIAM COURT, 1ST FLOOR, DUBLIN 2

Employee

Twitter

Next Earnings Date

2024-08-14

Latest SEC Filings

ITRM's Discussions on Twitter

Compare ITRM with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ITRM Iterum Therapeutics Plc	1.77	48.70M	0	-35.58M	-42.82M	-2.65
VRTX Vertex Pharmaceuticals Inc	397.27	102.31B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	701.85	77.13B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	623.82	37.30B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	245.44	31.66B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	113.08	27.11B	3.30B	-501.07M	1.03B	-2.1146

Iterum Therapeutics Plc Stock (ITRM) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-28-21	Upgrade	Gabelli & Co	Sell → Hold
Mar-15-21	Upgrade	H.C. Wainwright	Neutral → Buy
Jun-02-20	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Jan-21-20	Downgrade	Gabelli & Co	Buy → Sell
Dec-11-19	Downgrade	SVB Leerink	Outperform → Mkt Perform
Jun-21-19	Initiated	H.C. Wainwright	Buy

View All

Iterum Therapeutics Plc Stock (ITRM) Latest News

Dec 07, 2024

Iterum Therapeutics to Host Morning Conference Call on U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections - The Eastern Progress Online

Dec 07, 2024

Dec 02, 2024

Iterum Therapeutics stock hits 52-week high at $2.35 By Investing.com - Investing.com UK

Dec 02, 2024

Nov 23, 2024

Metrics That Matter About Iterum Therapeutics Plc (NASDAQ: ITRM) - Stocks Register

Nov 23, 2024

Nov 21, 2024

Iterum Therapeutics Regains Full Nasdaq Compliance - The Manila Times

Nov 21, 2024

Nov 19, 2024

Iterum Therapeutics to Host Morning Conference Call on U.S. FDA - GuruFocus.com

Nov 19, 2024

Nov 15, 2024

Iterum Therapeutics plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 15, 2024

Iterum Therapeutics plc (NASDAQ:ITRM) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 15, 2024